Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CHMP OKs Drugs For MS, Esophagitis, CMV & Hemophilia – And First EU Biosimilar Avastin

Nov 13 2017

• By Ian Schofield

Recommendation — The CHMP has recommended 10 new products for EU approval.

Related Content

Roche Finally Gets EU CHMP OK For Ocrevus Amid Access Concerns

Nov 10 2017

EU CHMP To Review July Rejection Of Drugs For Schizophrenia, Metastatic Breast Cancer

Nov 08 2017

Not Just Herceptin Biosimilar: Additional 12 Drugs Set For EU Marketing Approval After CHMP Nod

Sep 15 2017

Roche Fails Again To Convince CHMP On Ocrevus, Only Teva Gets A Thumbs Up

Oct 13 2017

Questions Surround Merck’s Withdrawal Of Keytruda Filing For Lung Cancer In EU

Oct 30 2017

Related Companies

AstraZeneca PLC

Roche Holding AG

Merck & Co., Inc.

Endoceutics Inc.

Amgen, Inc.

Novo Nordisk A/S

Clovis Oncology, Inc.

Vanda Pharmaceuticals, Inc.

Nektar Therapeutics

Takeda Pharmaceutical Co. Ltd.

Gilead Sciences, Inc.

Vertex Pharmaceuticals Incorporated

Additional Topics

Europe Drug Review Approvals Research & Development BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window